77 research outputs found
Optical properties of cometary particles collected by the COSIMA mass spectrometer on-board <i>Rosetta</i> during the rendezvous phase around comet 67P/Churyumov–Gerasimenko
40 000 collected cometary particles have been identified on the 21 targets exposed by the COSIMA experiment on-board Rosetta to the environment of comet 67P/Churyumov–Gerasimenko from 2014 August to 2016 September. The images of the targets where obtained by the COSIMA microscope (Cosiscope, 13.95 μm pixel−1) with near grazing incidence, which is optimal for the primary objective (detection of collected particles) but very challenging for photometry. However, more than 300 of the collected particles are larger than 100 μm which makes it possible to derive constraints on the optical properties from the distribution of light levels within the particles. Two types of particles collected by COSIMA (compact particles and cluster particles) have been identified in Langevin et al. The best estimate reflectance factors of compact particles range from 10 per cent to 23 per cent. For cluster particles (>90 per cent of large collected particles), the comparison of the signal profiles with illumination from two opposite directions shows that there is scattering within the particles, with a mean free path in the 20–25 μm range, which requires high porosity. The best estimate reflectance factors of cluster particles range from 3 per cent to 22 per cent. This range of reflectance factors overlaps with that obtained from observations of the cometary nucleus at macroscopic scales by OSIRIS and it is consistent with that measured for interplanetary dust particles collected in the stratosphere of the Earth
Optical properties of cometary particles collected by the COSIMA mass spectrometer on-board Rosetta during the rendezvous phase around comet 67P/Churyumov–Gerasimenko
40 000 collected cometary particles have been identified on the 21 targets exposed by the COSIMA experiment on-board Rosetta
to the environment of comet 67P/Churyumov–Gerasimenko from 2014 August
to 2016 September. The images of the targets where obtained by the
COSIMA microscope (Cosiscope, 13.95 μm pixel−1) with near
grazing incidence, which is optimal for the primary objective (detection
of collected particles) but very challenging for photometry. However,
more than 300 of the collected particles are larger than 100 μm which
makes it possible to derive constraints on the optical properties from
the distribution of light levels within the particles. Two types of
particles collected by COSIMA (compact particles and cluster particles)
have been identified in Langevin et al. The best estimate reflectance
factors of compact particles range from 10 per cent to 23 per cent. For
cluster particles (>90 per cent of large collected particles), the
comparison of the signal profiles with illumination from two opposite
directions shows that there is scattering within the particles, with a
mean free path in the 20–25 μm range, which requires high porosity. The
best estimate reflectance factors of cluster particles range from
3 per cent to 22 per cent. This range of reflectance factors overlaps
with that obtained from observations of the cometary nucleus at
macroscopic scales by OSIRIS and it is consistent with that measured for
interplanetary dust particles collected in the stratosphere of the
Earth.</p
Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis
<p>Abstract</p> <p>Background</p> <p>Levels of pentosidine (representative of advanced glycation end-products) in sera of patients with rheumatoid arthritis are increased when compared with sera of other diagnoses or healthy controls. These levels have been reported to correlate with clinical indices of rheumatoid arthritis activity and with laboratory markers of inflammation. The purpose of this study was to find out if these findings pertain to other advanced glycation end-products.</p> <p>Methods</p> <p>We have developed two immunoassays based on new monoclonal antibodies to advanced glycation end-products. Antibody 103-E3 reacts with an unidentified antigen, formed in the reaction of proteins with ribose, while antibody 8-C1 responds to N<sup>ε</sup>-(carboxyethyl)lysine. We have used these monoclonal antibodies to measure levels of advanced glycation end-products in sera of patients with rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and healthy controls. We calculated the correlations between advanced glycation end-product levels in rheumatoid arthritis sera and the Disease Activity Score 28 (DAS28), age, disease duration, CRP, anti-CCP, rheumatoid factor and treatment with corticosteroids, respectively.</p> <p>Results</p> <p>Levels of both glycation products were significantly higher in sera of patients with rheumatoid arthritis when compared with sera of patients with systemic lupus erythematosus, osteoarthritis, or the healthy controls. Neither the level of N<sup>ε</sup>-(carboxyethyl)lysine nor the level of the 103-E3 antigen in rheumatoid arthritis sera correlated with the DAS28-scored rheumatoid arthritis activity. The levels of both antigens in rheumatoid arthritis sera did not correlate with age, gender, corticosteroid treatment, or levels of CRP, anti-CCP antibodies, and rheumatoid factor in sera.</p> <p>Conclusions</p> <p>We report highly specific increases in the levels of two advanced glycation end-products in sera of patients with rheumatoid arthritis. This increase could be explained neither by rheumatoid arthritis activity nor by inflammation. We propose a working hypothesis that presumes the existence of a link between advanced glycation end-product formation and induction of autoimmunity.</p
Flexible intramedullary nails with traction versus plaster cast for treating femoral shaft fractures in children: comparative retrospective study
Toxocariasis: a silent threat with a progressive public health impact
Background: Toxocariasis is a neglected parasitic zoonosis that afflicts millions of the pediatric and adolescent populations worldwide, especially in impoverished communities. This disease is caused by infection with the larvae of Toxocara canis and T. cati, the most ubiquitous intestinal nematode parasite in dogs and cats, respectively. In this article, recent advances in the epidemiology, clinical presentation, diagnosis and pharmacotherapies that have been used in the treatment of toxocariasis are reviewed.
Main text: Over the past two decades, we have come far in our understanding of the biology and epidemiology of toxocariasis. However, lack of laboratory infrastructure in some countries, lack of uniform case definitions and limited surveillance infrastructure are some of the challenges that hindered the estimation of global disease burden. Toxocariasis encompasses four clinical forms: visceral, ocular, covert and neural. Incorrect or misdiagnosis of any of these disabling conditions can result in severe health consequences and considerable medical care spending. Fortunately, multiple diagnostic modalities are available, which if effectively used together with the administration of appropriate pharmacologic therapies, can minimize any unnecessary patient morbidity.
Conclusions: Although progress has been made in the management of toxocariasis patients, there remains much work to be done. Implementation of new technologies and better understanding of the pathogenesis of toxocariasis can identify new diagnostic biomarkers, which may help in increasing diagnostic accuracy. Also, further clinical research breakthroughs are needed to develop better ways to effectively control and prevent this serious disease
Lancet
BACKGROUND: In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. METHODS: CONCORD-3 includes individual records for 37.5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights. FINDINGS: For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89.5% in Australia and 90.2% in the USA, but international differences remain very wide, with levels as low as 66.1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68.9%), colon (71.8%), and rectum (71.1%); in Japan for oesophageal cancer (36.0%); and in Taiwan for liver cancer (27.9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59.9% in South Korea, 52.1% in Taiwan, and 49.6% in China), and for both lymphoid malignancies (52.5%, 50.5%, and 38.3%) and myeloid malignancies (45.9%, 33.4%, and 24.8%). For children diagnosed during 2010-14, 5-year survival for acute lymphoblastic leukaemia ranged from 49.8% in Ecuador to 95.2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28.9% in Brazil to nearly 80% in Sweden and Denmark). INTERPRETATION: The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer. FUNDING: American Cancer Society; Centers for Disease Control and Prevention; Swiss Re; Swiss Cancer Research foundation; Swiss Cancer League; Institut National du Cancer; La Ligue Contre le Cancer; Rossy Family Foundation; US National Cancer Institute; and the Susan G Komen Foundation
Overview of automotive engine friction and reduction trends–Effects of surface, material, and lubricant-additive technologies
A Metropolitan Area Network for Teleradiology and Remote Expert Consultation Based on ISDN
Physical Properties of Dust Particles Collected by the COSIMA Instrument on Board ROSETTA
- …